Welcome to our dedicated page for Amphastar Pharmaceuticals SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Amphastar Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Amphastar Pharmaceuticals's regulatory disclosures and financial reporting.
Amphastar Pharmaceuticals (AMPH) – SEC Form 4
Director Floyd F. Petersen disclosed the sale of 500 common shares on 01 Aug 2025 at a weighted-average price of $20.8315. The transaction was executed under a Rule 10b5-1 trading plan adopted 26 Nov 2024, indicating it was pre-scheduled rather than discretionary. After the sale, Petersen directly owns 77,031 shares, so the disposition equals roughly 0.6 % of his stake and is immaterial relative to Amphastar’s total share count. No derivative securities activity or additional insider trades were reported.
The filing therefore conveys routine insider diversification without signaling a change in corporate fundamentals or outlook.
Form 4 Overview – Amphastar Pharmaceuticals, Inc. (AMPH)
Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen’s direct ownership stands at 77,531 shares.
No derivative securities were involved and no other transactions were reported.
- Percentage of holdings sold: roughly 0.6 % of the director’s reported stake.
- The filing indicates continued direct ownership; no change to indirect holdings was reported.
- Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.
Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.